Early invasive treatments in patients with acute heart failure (AHF) are critical components to improve outcome. We aimed to establish if such treatments were applied according to existing guidelines and also to assess the subsequent mortality in the complete AHF population. All patients with AHF admitted to the intensive care unitycoronary care unit during the years 2003-2004 (ns302) were retrospectively reviewed and classified according to the European Society of Cardiology. Invasive revascularization was applied more frequently in patients with cardiogenic shock following acute coronary syndromes (78%, ns40) than in less severe AHF (58%, ns62, P-0.05). Only 8% (ns4) of eligible patients with acute coronary syndromes and cardiogenic shock were treated non-invasively. Valvular dysfunction was a precipitating factor for AHF in 15% (ns38). Acute mitral regurgitation was treated surgically exclusively in patients with mechanical defects. In-hospital mortality rates for less severe AHF was 12%, cardiogenic shock 46% and postcardiotomy HF 32%. Invasively treated patients had lower inhospital mortality in both cardiogenic shock (35% vs. 70%, Ps0.006) and less severe AHF (6% vs.17%, Ps0.042). The study revealed an appropriate use of invasive revascularization. The high mortality in patients with severe AHF indicates that more effective treatment options are needed in eligible patients.
Introduction
The European Society of Cardiology (ESC) introduced a first-time classification of acute heart failure (AHF) in 2005 w1x. Following this categorization, the EuroHeart Failure Survey-II (EHFS-II) was published in 2006 assessing the general AHF population in several European centers w2x. Acute coronary syndromes (ACS) and valvular dysfunction were reported to be precipitating factors in respectively 72% and 17% of patients with cardiogenic shock (CS). Less than two-thirds of these patients were revascularized (PCI or CABG) indicating an insufficient use of revascularization. The management of patients with valvular dysfunction was not described. This is an important issue, as a major question to evaluate when assessing treatment effects, is whether the invasive treatment rate and timing are optimal and compatible with recommended guidelines w1, 3, 4x.
In the present study we describe all patients with AHF treated in the CCU and ICU at the University Hospital North Norway during [2003] [2004] , also including patients with AHF after cardiac surgery. The main purpose of the study was to analyze the use of invasive treatments, i.e. PCI, CABG and valve procedures, and to assess whether such procedures were done according to guidelines, particularly in individuals with CS. In addition, we assessed outcome to clarify to what extent the presented treatment strategy is sufficient.
Methods
The study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Regional Ethics Committee.
All patients admitted to the ICU or CCU through the years 2003-2004 with evidence of AHF were enrolled retrospectively. Eligible patients were screened based on discharge diagnosis of 'heart failure', 'myocardial infarction (MI)' or 'unstable angina'. Patients with AHF following major noncardiac surgery (ns22) were excluded. The presented data were collected by the investigators from medical records using a structured case report form. Survival status and time of death for each individual patient were obtained from the Norwegian Cause of Death Registry two years after the index hospitalization.
Patients were classified into different AHF conditions based on the current ESC guidelines w1, 2x. Less severe AHF 
All patients except AHF after non-cardiac surgery (ns22). Postcardiotomy HF includes only patients without signs of acute heart failure before surgery. In order to clarify whether invasive treatment was applied according to relevant guidelines, patients with AHF following ACS andyor severe valvular pathology were assessed for type of invasive treatment given. Patients with CS not receiving recommended invasive treatment were reviewed separately to assess eligibility for invasive treatment.
Statistics
Categorical data are presented in frequencies and percentages and compared using x -test or Fisher's exact test 2 as appropriate. Continuous data are given as mean with standard deviation (S.D.) or median with interquartile range. Kaplan-Meier survival curves and log-rank test were used to compare cumulative mortality rates through a twoyear observation period. A two-sided P-value of -0.05 was considered statistically significant.
Results
A total of 302 patients were admitted to the CCUyICU with AHF over the two-year period ( Table 1) . Less severe forms of AHF were seen in 62% of the cases. CS accounted for 23% and PC-HF for 15%, representing the two most severe forms of AHF. Cardiovascular morbidities were abundant and as many as 40% had prior MI. ACS were by far the most common precipitating factors for AHF (57%), and the vast majority of these patients had evidence of AMI. Thirty percent presented with arrhythmias usually concomitant with other precipitating factors. Severe valvular dysfunction was considered a precipitating factor in 13% of all patients and 20% of CS patients.
Results of diagnostic investigations are given in Table 2 . Angiography was performed in 42% of all patients and most frequently in CS patients (70%). Three-vessel disease was present in 40%. The majority of patients had a normal or moderately reduced left ventricular ejection fraction regardless of clinical class.
Invasive treatment of AHF following ACS
Invasive and supportive treatments for AHF following ACS are presented in Table 3 . Revascularization was more frequent among CS patients compared to less severe AHF (78% vs. 58%, Ps0.012). Patients with CS following ACS not receiving invasive revascularization during hospitalization (ns11, 22%) are presented in Table 4 . An individual review revealed that only four of these patients (8%) were untreated potential candidates for coronary angiography and invasive revascularization. All were octogenarians with a history of MI or prior invasive revascularization and none survived. The presence of severe comorbidities was the reason for not performing angiography in those patients where this was technically feasible.
Valvular pathology
Moderate or severe mitral regurgitation (MR) was present in almost one-third of all patients ( Table 2) . Severe MR was observed in 13% (ns8) of CS patients and seven of these Table 2 Echocardiography, laboratory tests, chest X-ray, coronary angiography had AMI. One patient received urgent surgery due to a ruptured papillary muscle while the remaining patients were revascularized or treated conservatively. Six patients presented with severe aortic valve stenosis or aortic regurgitation. Acute valve replacement surgery was performed in three patients. Two patients were only revascularized because of concomitant AMI. One patient was not considered candidate for invasive therapy. Severe MR was observed in 6% (ns10) and severe aortic valve dysfunction in 8% (ns13) of the patients with less severe AHF. Valvular surgery was performed during index hospitalization in only three patients with severe MR due to rupture of the papillary muscle and endocarditis.
Mortality
Mortality rates and two-year survival curves are presented in Table 5 and Fig. 1 . CS had the worst prognosis with an in-hospital mortality of 46% compared to 13% in patients with less severe AHF. The majority of CS fatalities occurred within two days after admission. Two-year survival was worse for CS compared to PC-HF (log-rank Ps0.004) and less severe AHF (log-rank P-0.001). No difference was observed between PC-HF and less severe AHF (log-rank Ps0.064). Two-year mortality rates for hospital survivors were similar when comparing CS and less severe AHF Fig. 1 . Kaplan-Meier survival curves for cardiogenic shock, postcardiotomy HF and less severe AHF (i.e. acute decompensated heart failure, pulmonary edema, hypertensive acute heart failure and right heart failure).
(Ps0.709), while a significantly better two-year survival was observed for the discharged PC-HF patients (Ps0.009).
Invasively treated patients with less severe AHF had lower in-hospital mortality compared to patients treated conservatively (6% vs. 17%, Ps0.042). This was similar in the subset of patients with ACS (6% vs. 20%, Ps0.028). Likewise, CS patients treated invasively had improved outcome both in the overall population (35% vs. 70%, Ps0.006) and ACS subgroup (34% vs. 80%, Ps0.009).
Discussion

Invasive treatment and mortality in CS
In accordance with existing guidelines, advocating an early invasive strategy there was an extensive use of invasive revascularization for patients with CS following ACS w1, 3, 5x. Conservatively treated patients were octogenarians with partly severe comorbidities or previous revascularization attempts. These aspects most likely have affected the decision toward conservative treatment and indicate an appropriate selection of patients for invasive revascularization. Early invasive revascularization seems beneficial in clinically-selected elderly patients, but this has not been confirmed in randomized trials w5-7x.
A reported invasive revascularization frequency in EHFS-II around two-thirds of CS patients and 43% in the GRACE registry, indicates a restrictive utilization of invasive revascularization compared to existing guidelines w2, 5x. In contrast, 78% of CS patients in our survey received revascularization. We did not, however, observe a more satisfactory in-hospital outcome compared to the EHFS-II. One possible explanation could be that the beneficial effects of aggressive revascularization are only apparent long-term. Mortality rates for CS of any cause in our material were comparable with early and long-term mortality found in the EFICA study of severe AHF w8x.
Compared to other patient materials, the use of surgery (24%) was high in CS due to ACS w2, 5, 7x. The role of CABG in the acute phase of STEMI and CS is somewhat unclear. The AHAyACC guidelines state that CABG should be used if there is a suitable anatomy (main stem, three-vessel disease) and PCI fails to adequately reperfuse the myocardium or cannot be done w9x. Importantly, approximately 40% of the patients revascularized early in the SHOCK trial were treated with CABG with no higher mortality than patients treated by PCI w10x. Also, the two interventions seem to be comparable in high-risk populations w11x. By attacking the culprit lesions only, there is a risk of inadequate revascularization in some of these patients w12x. Potentially, the rather disappointing effects of revascularization could be improved by allocating more patients to early complete revascularization by CABG as the majority of CS patients presented with multi-vessel disease.
The presence of severe MR (13%) was comparable with the findings in EHFS-II. This was secondary to left ventricular dysfunction in the majority of patients and treated with revascularization or conservative treatment only. In contrast, close to half of the patients with severe MR received valvular surgery in the SHOCK trial registry w13x. The proportion of these patients with MR secondary to left ventricular dysfunction vs. acute mechanical dysfunction (e.g. papillary muscle rupture), is not reported. This could potentially explain the difference in the management of these patients. In addition, there is no definite evidence guiding the choice between revascularization and stabilization vs. prompt valve repair or replacement when MR follows left ventricular dilatation in AHF.
The use of mechanical circulatory assistance (IABP) was surprisingly low despite being a recommended therapy for CS in particular. A potential under-utilization of IABP was also apparent in EHFS-II (31%) and the NRMI registry (39%) w2, 7x. Since this survey, we have instituted IABP as a routine modality in CS.
Invasive treatment and mortality in less severe AHF
Less severe forms of AHF have received much less attention than CS with regard to invasive revascularization. The revascularization frequency observed in our study (58%) was substantially higher than reported from both the NRMI and GRACE registries (20-36%) w14, 15x. Despite similar inhospital mortality rates of 14%, the reported long-term survival in the GRACE registry was better. This reflects the strikingly high intermediate-term mortality for hospital survivors observed in our patients. A selection of CCUyICU patients and not the general AHF population, could explain this difference. Mortality rates for less severe AHF of any cause were also a lot higher than reported in EHFS-II, but comparable to the findings in the EFICA study on ICUyCCU patients w2, 8x.
Severe valvular dysfunction was less frequent in less severe AHF compared to CS, mostly due to a difference in the presence of MR. Surgical treatment of acute MR was only performed in the setting of acute papillary muscle rupture or dysfunction and endocarditis.
The dismal long-term prognosis for patients with less severe AHF underlines the need for close surveillance after discharge in this CCUyICU treated population.
Postcardiotomy HF
PC-HF constituted a significant part of the AHF population treated in the CCUyICU. Short-term prognosis was dismal compared to less severe AHF, but better than for CS. Twoyear mortality for hospital survivors was, however, substantially better compared to any of the other AHF conditions. These patients are all treated with complete surgical correction, and for logistical reasons, always receive a high level of medical attention and surveillance making early application of appropriate therapy possible.
Study limitations
The single center retrospective design increases the risk of missing patients eligible for inclusion, has a potential for selection bias and limits generalization of the results. Data on previous medical history are also likely to be under-reported because they are obtained in a clinical setting. Importantly, the exact timing of revascularization could not be assessed accurately for our patients.
Conclusion
The AHF patients were mainly treated according to relevant guidelines. However, the mortality for these patients is still high, and more effective treatment options, like assist devices, are needed in eligible patients.
